Article Details - Overview
Case Studies in Lymphoma Vol. 6, No. 2
Release Date: May 5, 2008
Expiration Date: May 5, 2009
Publication Overview
Author
Richard L. Piekarz, MD, PhD
Overview and Purpose
T-cell lymphomas (TCLs), which include cutaneous TCL and peripheral TCL (PTCL), account for 10% of all non-Hodgkin lymphomas and are challenging malignancies to treat due to disease heterogeneity, chemotherapy resistance, and lack of available targeted therapies. While standard first-line therapy for PTCL is similar to that used to treat B-cell lymphomas, no standard second-line therapy exists for PTCL. However, second-line therapeutic options have been developed and are under investigation in that disease, including anti-CD52 antibodies, proteasome inhibitors, chemotherapeutic agents, and immunotoxins. Histone deacetylase inhibitors (HDACIs) also represent a new class of agents that have demonstrated clinical efficacy and a manageable toxicity profile in patients with PTCL.
The purpose of this activity is to update physicians on the use of HDACIs in the treatment of patients with PTCL.
Target Audience
This activity is intended for medical oncologists and hematologists involved in the care of patients with peripheral T-cell lymphoma. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Learning Objectives
- Outline the safety of HDACIs in PTCL
- Summarize the recommended treatment options for patients with relapsed/refractory PTCL
- Evaluate the efficacy of HDACIs in PTCL
Instructions for Participation
- Read the following information before entering the educational activity.
- Study the educational activity.
- Complete the CME test.
- Answer the evaluation questions.
- After successful completion of the CME test and evaluation, you will receive your certificate of credit online.
- CME credit will be granted for only 1 form of participation, either online or via the printed publication.
You will be asked to login
or create an account.